Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rikisha Shah-Gupta"'
Autor:
J. Daniel Kelly, Tristan Curteis, Aaditya Rawal, Molly Murton, Laura J. Clark, Zarena Jafry, Rikisha Shah-Gupta, Mark Berry, Aprille Espinueva, Linda Chen, Mazin Abdelghany, Daniel A. Sweeney, Jennifer K. Quint
Publikováno v:
European Respiratory Review, Vol 32, Iss 169 (2023)
Background Many individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes referred to as “long COVID”. Our objective was to conduc
Externí odkaz:
https://doaj.org/article/195d0e9f4b7b49e0969dfaf883597f55
Autor:
Nishanthan Rajakumaraswamy, S. Kovalchuk, Ruth Pettengell, Gilles Salles, Elisabeth Vandenberghe, Anna van Troostenburg, Susana Carvalho, Annalisa Chiarenza, Ka Lung Wu, Paolo Corradini, Rikisha Shah Gupta, Christophe De Belder, Santiago Mercadal, Heribert Ramroth
Publikováno v:
Blood. 136:48-50
Introduction: Idelalisib, a selective oral inhibitor of PI3Kδ, was approved by the FDA and EMA as monotherapy for patients with advanced follicular lymphoma (FL) based on positive efficacy and safety results from the registration phase 2 trial in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40c6fc9166919b647c1d2dfc7f3794bf
https://doi.org/10.1182/blood-2020-137607
https://doi.org/10.1182/blood-2020-137607
Autor:
Emmanuel Gyan, Francesco Di Raimondo, Francesco Merli, Anthony Boland, Heribert Ramroth, Rikisha Shah Gupta, Benedetta Puccini, Luca Baldini, Maria Chiara Tisi, Carolyn Dunnill, Anna van Troostenburg, Gilles Salles, Nishanthan Rajakumaraswamy, Santiago Mercadal, Ka Lung Wu, Elisabeth Vandenberghe
Publikováno v:
Blood. 138:1350-1350
Background: Malignant lymphoid cells are characteristically dependent on signals mediated by the phosphatidylinositol 3-kinase delta isoform (PI3Kδ). Idelalisib is an oral, selective, PI3Kδ inhibitor approved by the FDA and EMA as monotherapy for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9225c4d054ddee1f248b0ac525d34e4f
https://doi.org/10.1182/blood-2021-146066
https://doi.org/10.1182/blood-2021-146066
Autor:
Michael J. Eckrote, Carrie M. Nielson, Mike Lu, Tyler Alexander, Rikisha Shah Gupta, Kim Wah Low, Zhiwei Zhang, Austin Eliazar, Reyna Klesh, Andrew Kress, Matt Bryant, Alex Asiimwe, Nicolle M. Gatto, Nancy A. Dreyer
Publikováno v:
Contemporary Clinical Trials Communications, Vol 41, Iss , Pp 101354- (2024)
In drug development, the use of real-world data (RWD) has augmented our understanding of patients’ health care experiences and the effects of treatments beyond clinical trials. Although electronic health record (EHR) data integration at clinical tr
Externí odkaz:
https://doaj.org/article/a59ff5c32e22499a909e1901e20a6b10
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Routinely-collected healthcare data provide a valuable resource for epidemiological research. Validation studies have shown that for most conditions, simple lists of clinical codes can reliably be used for case finding in primary
Externí odkaz:
https://doaj.org/article/b01a22c075954a5c869ed757b14269ff
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of guidance and updates to diagnostic criteria over time, it has been
Externí odkaz:
https://doaj.org/article/d500b707dd294bc1b68cc14213498e90